Pfenex, Inc. has awarded Paragon Bioservices a contract for the cGMP manufacture of its rPA-based anthrax vaccine. Paragon will implement the cGMP-ready Pfenex Expression Technology-based production process that has been developed at Pfenex. The contract will be funded by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).   “We are pleased to award this contract to Paragon Bioservices,” said Bertrand C. Liang...